We analyzed the association of NCF2 levels with BLCa patient prognosis and found that OS and DSS of patients with higher NCF2 expression was significantly poorer than patients with relatively lower NCF2 expression (Fig. 5H, I). The gene discussed is NCF2; the disease is bladder transitional cell carcinoma.